Cysteamine: new preparation. Chronic treatment of cystinosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Prescrire international [Prescrire Int] 1999 Jun; Vol. 8 (41), pp. 67-70.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Association Mieux Prescrire Country of Publication: France NLM ID: 9439295 Publication Model: Print Cited Medium: Print ISSN: 1167-7422 (Print) Linking ISSN: 11677422 NLM ISO Abbreviation: Prescrire Int
    • Publication Information:
      Original Publication: Paris : Association Mieux Prescrire, [1992-
    • Subject Terms:
      Cysteamine*/adverse effects ; Cysteamine*/therapeutic use ; Radiation-Protective Agents*/adverse effects ; Radiation-Protective Agents*/therapeutic use; Cystinosis/*drug therapy; Adolescent ; Child ; Child, Preschool ; Clinical Trials as Topic ; Europe ; Humans ; Infant ; Treatment Outcome
    • Abstract:
      (1) Cysteamine bitartrate (also known as mercaptamine) is marketed for the treatment of cystinosis, a rare hereditary disease which, in its juvenile and infantile forms, progresses spontaneously to severe renal and ocular impairment, growth retardation with rickets, and involvement of many other organs. Only symptomatic treatments have been available until now. (2) The clinical file includes only non comparative trials. (3) Few children have been treated with cysteamine beyond the age of 10. Provided treatment is begun early, the main beneficial effects of cysteamine are maintenance of the growth curve and prevention of deterioration of renal lesions (an effect that varies from patient to patient). Oral cysteamine does not prevent the progression of ocular lesions. (4) Cysteamine has many potential adverse effects, some of which are serious (mainly gastrointestinal and neuropsychiatric disorders). Little is known of its long-term adverse effects. (5) The main disadvantage of this treatment is the need for four daily intakes (every 6 hours) and the sulphurous breath it causes. (6) Treatment with cysteamine is expensive.
    • Accession Number:
      0 (Radiation-Protective Agents)
      5UX2SD1KE2 (Cysteamine)
    • Publication Date:
      Date Created: 19991111 Date Completed: 19991109 Latest Revision: 20131121
    • Publication Date:
      20221213
    • Accession Number:
      10558441